Polaryx Therapeutics, Inc.(PLYX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PLYX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Polaryx Therapeutics, Inc. (PLYX), a Healthcare sector company. PLYX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Polaryx Therapeutics, Inc. reports net income of $-2.5M, free cash flow of $-2.1M. Top institutional holders of PLYX by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. PLYX trades on the Nasdaq exchange and files with the SEC under CIK 2075320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PLYX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Polaryx Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-2.5M
Free Cash Flow
Q1 2026
$-2.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
Operating Income
EPS (Diluted)
Total Assets
Op. Cash Flow
| Metric | FY 2024 | FY 2023 |
|---|---|---|
| Net Income | $-30.4M | — |
| Operating Income | $-4.4M | — |
| EPS (Diluted) | $-0.89 | — |
| Total Assets | $5.0M | — |
| Operating Cash Flow | $-2.6M | — |
AI Insight: PLYX Financial Trends
Polaryx burned $3M net loss in Q1 2026 with equity halved to $2M; pre-revenue biotech in cash-preservation mode.
• Operating loss of $2M matched operating cash burn in Q1 2026; no revenue generation yet.
• Shareholder equity collapsed from $5M to $2M between Q4 2025 and Q1 2026.
⚠ Equity base of $2M provides minimal runway for development; debt position and cash reserves unknown.
⚠ No revenue reported; company depends entirely on external funding or capital raises.
AI Insight: PLYX Ratio Trends
Insufficient financial data to establish trends — both Q4 2025 and Q1 2026 lack core profitability and return metrics.
• No operating margin, net profit margin, ROE, ROA, or ROIC data available for either period.
⚠ D/E ratio also absent — leverage position cannot be assessed. Await earnings disclosure.
Get alerted when PLYX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Polaryx Therapeutics, Inc. including:
Top Institutional Holders of PLYX
VANGUARD CAPITAL MANAGEMENT LLC
$12.5M1,658,388 shGEODE CAPITAL MANAGEMENT, LLC
$1.3M170,673 shMILLENNIUM MANAGEMENT LLC
$964.1K127,525 shVANGUARD FIDUCIARY TRUST CO
$790.4K104,556 shSTATE STREET CORP
$439.3K58,104 shBlackRock, Inc.
$310.1K41,012 shNORTHERN TRUST CORP
$211.6K27,987 shBANK OF AMERICA CORP /DE/
$195.7K25,881 shGOLDMAN SACHS GROUP INC
$101.9K13,483 shUBS Group AG
$101.9K13,479 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $12.5M | 1,658,388 |
| GEODE CAPITAL MANAGEMENT, LLC | $1.3M | 170,673 |
| MILLENNIUM MANAGEMENT LLC | $964.1K | 127,525 |
| VANGUARD FIDUCIARY TRUST CO | $790.4K | 104,556 |
| STATE STREET CORP | $439.3K | 58,104 |
| BlackRock, Inc. | $310.1K | 41,012 |
| NORTHERN TRUST CORP | $211.6K | 27,987 |
| BANK OF AMERICA CORP /DE/ | $195.7K | 25,881 |
| GOLDMAN SACHS GROUP INC | $101.9K | 13,483 |
| UBS Group AG | $101.9K | 13,479 |
More Healthcare Companies
View all Healthcare →Put PLYX on your watchlist
Track score changes the day Polaryx Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PLYX a good stock to buy?
13F Pro's AI-powered analysis of Polaryx Therapeutics, Inc. (PLYX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PLYX are available on the PLYX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PLYX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PLYX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Polaryx Therapeutics, Inc.'s investment landscape.